STOCK TITAN

Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Adagene (ADAG) announced that the first patient received ADG138 in a first-in-human Phase 1 study for HER2-positive advanced solid tumors.

The open-label study, in which treatment is not concealed, will assess safety and look for early signs of effectiveness. It will also seek to determine the recommended Phase 2 dose. Dose escalation will start at 2 mg, with emerging clinical data guiding subsequent doses.

ADG138 is designed to engage T cells and has masks on its HER2 and CD3 binding sites. Adagene said double masking preserved antitumor activity in preclinical tests, including in models resistant to Enhertu. Compared with an unmasked T-cell engager, it reduced the release of immune signaling proteins called cytokines and widened the range between effective and toxic doses in preclinical testing.

Loading...
Loading translation...
5 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointFirst patient dosed moves ADG138 into first-in-human Phase 1 testing for HER2-positive advanced solid tumors
  • Minor point. Forward-looking: it has not happened yet and may not happen.Phase 1 study will assess safety and preliminary efficacy and seek to determine the recommended Phase 2 dose
  • Minor pointAntitumor activity was preserved with double masking in preclinical tests, including in Enhertu-resistant models
  • Minor pointCytokine release was lower in preclinical testing than with an unmasked T-cell engager
  • Minor pointTherapeutic window was wider in preclinical testing than with an unmasked T-cell engager

Negative

  • None.

Key Figures

First patient dosed: 1 patient dosed Starting dose: 2 mg
First patient dosed
1 patient dosed
ADG138 first-in-human Phase 1 study
Starting dose
2 mg
ADG138 Phase 1 dose escalation

Previous Clinical trial Reports

1 past event · Latest: Sep 22
Same Type 1 event
  1. Sep 22

    ADG138 IND clearance

    24h Move
    +0.6%

    China's NMPA cleared ADG138's IND and the company expected Phase 1 initiation in Q4 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

bispecific t-cell engager, open-label, dose escalation
3 terms
bispecific t-cell engager technical
"a double-masked HER2×CD3 bispecific T-cell engager built on an IgG1-based format"
A bispecific T‑cell engager is a lab-made protein that binds both a cancer cell and a patient’s immune T cell at the same time, bringing them together so the T cell can attack and kill the cancer cell. For investors, these drugs matter because they represent a targeted immunotherapy approach with potential for strong effectiveness but also unique safety and regulatory risks—think of it as a matchmaker that can unlock powerful results if it works safely and reliably.
open-label medical
"The open-label Phase 1 study is designed to evaluate the safety"
Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.
dose escalation medical
"Dose escalation will begin with a starting dose of 2 mg"
Dose escalation is the process of gradually increasing the amount of a treatment or substance over time. In finance, it can refer to slowly raising investments or commitments to manage risk and assess performance. For investors, understanding dose escalation helps gauge how companies or strategies adjust their approaches, which can impact future growth or stability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

First-in-human study will enroll patients with HER2-positive advanced solid tumors

ADG138 design includes proprietary IgG1-based heterodimeric format and SAFEbody® double masking to support prolonged circulation and tumor-selective accumulation and activation

SAN DIEGO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that the first patient has been dosed in a first-in-human Phase 1 study of ADG138, a double-masked HER2×CD3 bispecific T-cell engager built on an IgG1-based format and Adagene’s proprietary SAFEbody® precision masking technology.

“Dosing the first patient with ADG138 is an important step in moving our double-masked T-cell engager from preclinical research into the clinic,” said Peter Luo, Ph.D., Chairman, CEO and President of R&D at Adagene. “Our preclinical data showed that masking both the HER2 and CD3 binding sites preserved ADG138’s antitumor activity, including in Enhertu (DS-8201)-resistant models, while reducing cytokine release and widening the therapeutic window compared with an unmasked T-cell engager.

“Clinical experience with muzastotug, our masked anti-CTLA-4 SAFEbody in IgG1 format, now includes more than 250 patients dosed with high, repeated dosing, and continuous treatment beyond two years in some patients. Together with ADG138’s robust preclinical findings, this reinforces our confidence in extending SAFEbody technology to T-cell engagers. We look forward to evaluating ADG138’s safety and preliminary efficacy in heavily pretreated patients who have progressed after multiple lines of therapies, including standard-of-care and investigational HER2-directed antibody-drug conjugates.”

The open-label Phase 1 study is designed to evaluate the safety and preliminary efficacy of ADG138 in patients with HER2-positive advanced solid tumors and determine the recommended Phase 2 dose. Dose escalation will begin with a starting dose of 2 mg of ADG138, and subsequent doses will be guided by emerging clinical data.

About ADG138

ADG138 is a double-masked HER2×CD3 bispecific T cell engager designed using Adagene’s proprietary IgG-based heterodimeric format and SAFEbody® precision masking technology, which covalently links masking peptides to both the HER2- and CD3-binding arms of the molecule. In its inactivated state, ADG138 is designed to minimally bind HER2-expressing cancer cells and T cells; the molecule becomes activated within the tumor microenvironment and engages T cells to selectively kill HER2-expressing tumor cells while limiting off-target toxicity.

In preclinical models, the double-masked ADG138 has achieved approximately 220-fold and greater than 1,000-fold reductions in binding to HER2 and CD3, respectively, compared to its unmasked form. Upon activation in the tumor microenvironment, ADG138 enables highly efficient T cell-mediated tumor cell killing, driving tumor regression in both HER2-high and HER2-low tumor models, including a model refractory and/or resistant to the Enhertu (DS-8201). ADG138 has also shown synergistic anti-tumor activity in combination with anti-CTLA-4, anti-PD-1, or anti-CD137 antibodies. In addition, ADG138 was tolerated at doses over 300-fold higher than an unmasked T-cell engager, with markedly reduced cytokine release and a favorable pharmacokinetic profile, including a longer apparent half-life and higher systemic exposure than the parental molecule.

About Adagene

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.

Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.

Adagene’s lead clinical program, muzastotug (ADG126), is a masked, anti-CTLA-4 SAFEbody with FDA Fast Track designation that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. Muzastotug is currently in Phase 1b/2 and Phase 2 clinical studies in combination with anti-PD-1 therapy, particularly focused on microsatellite stable (MSS) metastatic colorectal cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc-empowered antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers.

For more information, please visit: https://investor.adagene.com.

Follow Adagene on WeChat, LinkedIn and X.

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Safe Harbor Statement

This press release contains forward-looking statements, including statements regarding ADG138’s potential therapeutic benefits, the intended effects of its dual-masking design, the objectives of its Phase 1 study and starting-dose strategy, and Adagene’s anticipated preclinical activities, clinical development, regulatory milestones and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Investor Contacts

Raymond Tam
Raymond_tam@adagene.com

Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com

Media Contact

Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Adagene testing in the Phase 1 study of ADG138?

Adagene is testing safety, early signs of effectiveness and what dose to recommend for Phase 2 in patients with HER2-positive advanced solid tumors.

What is the starting dose in Adagene's ADG138 Phase 1 study?

Dose escalation in the ADG138 study will start at 2 mg. Emerging clinical data will guide subsequent doses.

What prior treatments does Adagene expect patients in the ADG138 study to have received?

Adagene expects to evaluate patients whose cancer has progressed after multiple lines of treatment, including standard-of-care and investigational HER2-directed antibody-drug conjugates.

Keep reading